[go: up one dir, main page]

FR2649120B1 - NOVEL STRAIN AND ITS MUTANTS OF FILAMENTOUS MUSHROOMS, PROCESS FOR PRODUCING RECOMBINANT PROTEINS USING SAID STRAIN, AND STRAINS AND PROTEINS OBTAINED BY SAID METHOD - Google Patents

NOVEL STRAIN AND ITS MUTANTS OF FILAMENTOUS MUSHROOMS, PROCESS FOR PRODUCING RECOMBINANT PROTEINS USING SAID STRAIN, AND STRAINS AND PROTEINS OBTAINED BY SAID METHOD

Info

Publication number
FR2649120B1
FR2649120B1 FR8908838A FR8908838A FR2649120B1 FR 2649120 B1 FR2649120 B1 FR 2649120B1 FR 8908838 A FR8908838 A FR 8908838A FR 8908838 A FR8908838 A FR 8908838A FR 2649120 B1 FR2649120 B1 FR 2649120B1
Authority
FR
France
Prior art keywords
strain
proteins
mutants
strains
producing recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR8908838A
Other languages
French (fr)
Other versions
FR2649120A1 (en
Inventor
Calmels Thierry
Durand Henri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cayla
Original Assignee
Cayla
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cayla filed Critical Cayla
Priority to FR8908838A priority Critical patent/FR2649120B1/en
Priority to EP90910778A priority patent/EP0433431A1/en
Priority to PCT/FR1990/000479 priority patent/WO1991000357A1/en
Publication of FR2649120A1 publication Critical patent/FR2649120A1/en
Application granted granted Critical
Publication of FR2649120B1 publication Critical patent/FR2649120B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14Fungi; Culture media therefor
    • C12N1/145Fungal isolates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405Glucanases
    • C12N9/2451Glucanases acting on alpha-1,6-glucosidic bonds
    • C12N9/2457Pullulanase (3.2.1.41)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462Lysozyme (3.2.1.17)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01041Pullulanase (3.2.1.41)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00Microorganisms ; Processes using microorganisms
    • C12R2001/645Fungi ; Processes using fungi

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FR8908838A 1989-06-30 1989-06-30 NOVEL STRAIN AND ITS MUTANTS OF FILAMENTOUS MUSHROOMS, PROCESS FOR PRODUCING RECOMBINANT PROTEINS USING SAID STRAIN, AND STRAINS AND PROTEINS OBTAINED BY SAID METHOD Expired - Lifetime FR2649120B1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
FR8908838A FR2649120B1 (en) 1989-06-30 1989-06-30 NOVEL STRAIN AND ITS MUTANTS OF FILAMENTOUS MUSHROOMS, PROCESS FOR PRODUCING RECOMBINANT PROTEINS USING SAID STRAIN, AND STRAINS AND PROTEINS OBTAINED BY SAID METHOD
EP90910778A EP0433431A1 (en) 1989-06-30 1990-06-28 New strain with filamentous fungi mutants, process for the production of recombinant proteins using said strain, and strains and proteins produced by said process
PCT/FR1990/000479 WO1991000357A1 (en) 1989-06-30 1990-06-28 New strain with filamentous fungi mutants, process for the production of recombinant proteins using said strain, and strains and proteins produced by said process

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8908838A FR2649120B1 (en) 1989-06-30 1989-06-30 NOVEL STRAIN AND ITS MUTANTS OF FILAMENTOUS MUSHROOMS, PROCESS FOR PRODUCING RECOMBINANT PROTEINS USING SAID STRAIN, AND STRAINS AND PROTEINS OBTAINED BY SAID METHOD

Publications (2)

Publication Number Publication Date
FR2649120A1 FR2649120A1 (en) 1991-01-04
FR2649120B1 true FR2649120B1 (en) 1994-01-28

Family

ID=9383358

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8908838A Expired - Lifetime FR2649120B1 (en) 1989-06-30 1989-06-30 NOVEL STRAIN AND ITS MUTANTS OF FILAMENTOUS MUSHROOMS, PROCESS FOR PRODUCING RECOMBINANT PROTEINS USING SAID STRAIN, AND STRAINS AND PROTEINS OBTAINED BY SAID METHOD

Country Status (3)

Country Link
EP (1) EP0433431A1 (en)
FR (1) FR2649120B1 (en)
WO (1) WO1991000357A1 (en)

Families Citing this family (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69333127T2 (en) 1992-06-03 2004-05-06 Genentech, Inc., South San Francisco Variants of the tissue plasminogen activator with improved therapeutic effect
US5712249A (en) * 1994-09-08 1998-01-27 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
JPH11514976A (en) 1995-09-08 1999-12-21 ジェネンテク・インコーポレイテッド VEGF-related proteins
US20020193571A1 (en) 1996-01-08 2002-12-19 Paul J. Carter Wsx receptor agonist antibodies
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
ATE505478T1 (en) 1997-08-27 2011-04-15 Novartis Vaccines & Diagnostic MOLECULAR MIMETICS OF MENINGOCOCCAL B EPITOPES
ES2316173T3 (en) 1997-10-29 2009-04-01 Genentech, Inc. INDUCIBLE GENES BY WNT-1.
AU1288399A (en) 1997-10-29 1999-05-17 Genentech Inc. Wnt-1 induced secreted polypeptides: wisp-1, -2 and -3
NZ525914A (en) 1998-03-10 2004-03-26 Genentech Inc Novel polypeptides and nucleic acids encoding the same
EP3112468A1 (en) 1998-05-15 2017-01-04 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
EP1865061A3 (en) 1998-05-15 2007-12-19 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
EP1076703B2 (en) 1998-05-15 2010-12-15 Genentech, Inc. Therapeutic uses of il-17 homologous polypeptides
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
WO2001051635A2 (en) 2000-01-13 2001-07-19 Genentech, Inc. Novel stra6 polypeptides
JP2002527066A (en) 1998-10-15 2002-08-27 カイロン コーポレイション Metastatic breast and colon cancer regulatory genes
JP2003524389A (en) 1998-12-16 2003-08-19 カイロン コーポレイション Human cyclin dependent kinase (hPNQALRE)
CA2450402A1 (en) 1998-12-22 2000-06-29 Genentech, Inc. Methods and compositions for inhibiting cancer cell growth comprising pro224
DE60043322D1 (en) 1999-06-15 2009-12-24 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids for their coding
JP2003527833A (en) 1999-10-14 2003-09-24 クロンテック・ラボラトリーズ・インコーポレーテッド Chromophores / phosphors derived from flower insects and their use
EP1669371A3 (en) 1999-12-01 2006-06-21 Genentech, Inc. Composition and methods for the diagnosis of tumours
EP1897945B1 (en) 1999-12-23 2012-01-18 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
DE60134956D1 (en) 2000-01-10 2008-09-04 Novartis Vaccines & Diagnostic GENE DIFFERENTIALLY EXPERIMENTED IN BRUDTKREBS
WO2004043361A2 (en) 2002-11-08 2004-05-27 Genentech, Inc. Compositions and methods for the treatment of natural killer cell related diseases
EP2792747A1 (en) 2000-06-23 2014-10-22 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
CA2709771A1 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
EP2014298A3 (en) 2000-08-24 2009-10-07 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
EP1944317A3 (en) 2000-09-01 2008-09-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
AU2002258728A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
WO2002081639A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
WO2002081641A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
AU2002318371B2 (en) 2001-06-20 2006-06-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7172905B2 (en) 2001-08-07 2007-02-06 The University Of Chicago Polypeptide immobilization
JP4361791B2 (en) 2001-08-29 2009-11-11 ジェネンテック・インコーポレーテッド Bv8 nucleic acids and polypeptides having mitogenic activity
WO2003024392A2 (en) 2001-09-18 2003-03-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1456223B1 (en) 2001-12-19 2009-08-12 The University Of Chicago Rapidly maturing fluorescent proteins and methods for using the same
WO2003057160A2 (en) 2002-01-02 2003-07-17 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2388265A1 (en) 2002-02-22 2011-11-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7138512B2 (en) 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
KR20040101502A (en) 2002-04-16 2004-12-02 제넨테크, 인크. Compositions and Methods for the Diagnosis and Treatment of Tumor
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
AU2003243400B2 (en) 2002-06-07 2009-10-29 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2383278A1 (en) 2002-07-08 2011-11-02 Genentech, Inc. Method to determine B cell mediated diseases
JP2006521082A (en) 2002-09-11 2006-09-21 ジェネンテック・インコーポレーテッド Novel compositions and methods for the treatment of immune related diseases
EP1539228B1 (en) 2002-09-11 2010-12-29 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
EP2444409A2 (en) 2002-09-16 2012-04-25 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP2500438A3 (en) 2002-09-25 2012-11-28 Genentech, Inc. Novel compositions and methods for the treatment of psoriasis
EP2322203A3 (en) 2002-10-29 2011-07-27 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CA2504144A1 (en) 2002-11-26 2004-06-10 Genentech, Inc. Compositions and methods for the diagnosis of immune related diseases using pro7
CA2513113A1 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
AU2004219592C1 (en) 2003-03-12 2011-02-24 Genentech, Inc. Use of Bv8 and/or EG-VEGF to promote hematopoiesis
DK2335725T3 (en) 2003-04-04 2017-01-23 Genentech Inc Highly concentrated antibody and protein formulations
ES2371072T3 (en) 2003-06-12 2011-12-27 Eli Lilly And Company GLP-1 ANALOG FUSION PROTEINS.
PL1641822T3 (en) 2003-07-08 2013-10-31 Genentech Inc Heterologous IL-17 A / F polypeptides and their therapeutic applications
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
DE602004024921D1 (en) 2003-11-17 2010-02-11 Genentech Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF TUMORS OF HEMATOPOETIC ORIGIN
GB2426521A (en) 2004-02-02 2006-11-29 Ambrx Inc Modified human four helical bundle polypeptides and their uses
KR20120126130A (en) 2004-03-29 2012-11-20 가르파마 컴퍼니 리미티드 Novel galectin 9 modification protein and use thereof
US7250298B2 (en) 2004-04-07 2007-07-31 The University Of Chicago Monomeric red fluorescent proteins
CN102532321B (en) 2004-06-18 2018-10-12 Ambrx公司 Novel antigen-binding polypeptides and its purposes
CA2569381A1 (en) 2004-07-21 2006-08-31 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
US7939496B2 (en) 2004-12-22 2011-05-10 Ambrx, Inc. Modified human growth horomone polypeptides and their uses
US8080391B2 (en) 2004-12-22 2011-12-20 Ambrx, Inc. Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer
NZ555308A (en) 2004-12-22 2010-10-29 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
KR101252835B1 (en) 2004-12-22 2013-04-10 암브룩스, 인코포레이티드 COMPOSITIONS OF AMINOACYL-tRNA SYNTHETASE AND USES THEREOF
AU2005322019B2 (en) 2004-12-22 2010-08-26 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid
EP1865940B1 (en) 2005-03-21 2013-02-13 Virobay, Inc. Alpha ketoamide compounds as cysteine protease inhibitors
EP1891107B1 (en) 2005-05-12 2011-07-06 ZymoGenetics, Inc. Compositions and methods for modulating immune responses
KR20080026135A (en) 2005-06-03 2008-03-24 암브룩스, 인코포레이티드 Improved Human Interferon Molecules and Uses thereof
AU2006255686A1 (en) 2005-06-06 2006-12-14 Genentech, Inc. Transgenic models for different genes and their use for gene characterization
JP2009504183A (en) 2005-08-15 2009-02-05 ジェネンテック・インコーポレーテッド Gene disruption and related compositions and methods
NZ565294A (en) 2005-08-18 2010-06-25 Ambrx Inc Compositions of tRNA and uses thereof
WO2007053732A2 (en) 2005-11-01 2007-05-10 Mayo Foundation For Medical Education And Research Promoter polymorphisms of the blys gene and use in diagnostic methods
WO2007059312A2 (en) 2005-11-16 2007-05-24 Ambrx, Inc. Methods and compositions comprising non-natural amino acids
EP2002714A1 (en) 2005-11-21 2008-12-17 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
US20080311107A1 (en) 2006-02-17 2008-12-18 Genetech, Inc. Novel Gene Disruptions, Compositions and Methods Relating Thereto
EP2389950A1 (en) 2006-03-23 2011-11-30 Novartis AG Anti-tumor cell antigen antibody therapeutics
CA2647277A1 (en) 2006-04-05 2007-11-08 Genentech, Inc. Method for using boc/cdo to modulate hedgehog signaling
JP2009536022A (en) 2006-04-19 2009-10-08 ジェネンテック・インコーポレーテッド Novel gene disruption and related compositions and methods
EP3026123A1 (en) 2006-04-27 2016-06-01 Klaritos, Inc. Method and kit for predicting antibody therapy
US20080014205A1 (en) 2006-05-15 2008-01-17 Lawrence Horowitz Neutralizing Antibodies to Influenza Viruses
AU2007261315B2 (en) 2006-06-21 2012-10-25 Musc Foundation For Research Development Targeting complement factor H for treatment of diseases
EP2615108B1 (en) 2006-09-08 2016-10-26 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and thier uses
ES2465473T3 (en) 2006-09-08 2014-06-05 Ambrx, Inc. Transcription of arnt suppressor in vertebrate cells
AU2007292892B9 (en) 2006-09-08 2013-02-28 Ambrx, Inc. Hybrid suppressor tRNA for vertebrate cells
US7985783B2 (en) 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
EP2078040B1 (en) 2006-11-02 2017-06-28 Daniel J. Capon Methods of producing hybrid polypeptides with moving parts
WO2008103962A2 (en) 2007-02-22 2008-08-28 Genentech, Inc. Methods for detecting inflammatory bowel disease
KR20140012199A (en) 2007-03-30 2014-01-29 암브룩스, 인코포레이티드 Modified fgf-21 polypeptides and their uses
CA2685596A1 (en) 2007-05-02 2008-11-13 Ambrx, Inc. Modified interferon beta polypeptides and their uses
HUE061746T2 (en) 2007-07-09 2023-08-28 Genentech Inc Prevention of disulfide bond reduction during recombinant production of polypeptides
EP2641618A3 (en) 2007-07-16 2013-10-23 Genentech, Inc. Humanized anti-CD79B antibodies and immunoconjugates and methods of use
CN111499748A (en) 2007-07-16 2020-08-07 健泰科生物技术公司 anti-CD 79B antibodies and immunoconjugates and methods of use
CN101361968B (en) 2007-08-06 2011-08-03 健能隆医药技术(上海)有限公司 Use of interleukin-22 in treating fatty liver
KR101662622B1 (en) 2007-10-04 2016-10-05 지모제넥틱스, 인코포레이티드 B7 FAMILY MEMBER zB7H6 AND RELATED COMPOSITIONS AND METHODS
WO2009059305A2 (en) 2007-11-01 2009-05-07 The University Of Chicago Red fluorescent proteins with enhanced bacterial expression, increased brightness and reduced aggregation
DK2217265T3 (en) 2007-11-20 2017-07-03 Ambrx Inc Modified insulin polypeptides and their use
WO2009073511A2 (en) 2007-11-30 2009-06-11 Mayo Foundation For Medical Education And Research Polymorphisms of the blys gene and use in diagnostic methods
HUE029869T2 (en) 2008-01-31 2017-04-28 Genentech Inc Anti-CD79B antibodies and immunoconjugates, as well as application procedures
CN103694337B (en) 2008-02-08 2016-03-02 Ambrx公司 Modified leptin polypeptide and its purposes
EP2698380A1 (en) 2008-03-28 2014-02-19 Sea Lane Biotechnologies, LLC Neutralizing molecules to viral antigens
EP3605088A1 (en) 2008-04-09 2020-02-05 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2010011735A2 (en) 2008-07-23 2010-01-28 Ambrx, Inc. Modified bovine g-csf polypeptides and their uses
WO2010034015A2 (en) 2008-09-22 2010-03-25 The Regents Of The University Of Colorado, A Body Corporate Modulating the alternative complement pathway
AU2009296267B2 (en) 2008-09-26 2013-10-31 Ambrx, Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
JP5694171B2 (en) 2008-09-26 2015-04-01 アンブルックス, インコーポレイテッドAmbrx, Inc. Modified animal erythropoietin polypeptides and their use
EA020843B1 (en) 2009-02-03 2015-02-27 Амуникс Оперейтинг Инк. Extended recombinant polypeptides and compositions comprising same
TW201038286A (en) 2009-04-01 2010-11-01 Genentech Inc Anti-FcRH5 antibodies and immunoconjugates and methods of use
WO2010144508A1 (en) 2009-06-08 2010-12-16 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
CN103140236B (en) 2009-06-08 2017-04-19 阿穆尼克斯运营公司 Growth hormone polypeptides and methods of making and using same
WO2011047267A1 (en) 2009-10-15 2011-04-21 Genentech, Inc. Chimeric fibroblast growth factors with altered receptor specificity
RU2539772C2 (en) 2009-10-22 2015-01-27 Дженентек, Инк. Methods and compositions for hepsin modulation of macrophage-stimulating protein
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
AR078986A1 (en) 2009-11-12 2011-12-14 Genentech Inc A METHOD TO PROMOTE THE DENSITY OF DENDRITIC THORNS
JP5856065B2 (en) 2009-11-30 2016-02-09 ジェネンテック, インコーポレイテッド Compositions and methods for tumor diagnosis and treatment
JP2013515080A (en) 2009-12-21 2013-05-02 アンブルックス,インコーポレイテッド Modified bovine somatotropin polypeptides and their use
EA201290542A1 (en) 2009-12-21 2013-07-30 Амбркс, Инк. MODIFIED PORK SOMATOTROPINE POLYPEPTIDES AND THEIR APPLICATION
BR112012020373A8 (en) 2010-02-23 2018-01-02 Genentech Inc isolated antibody, cell, isolated nucleic acid, method of identification, cell proliferation inhibition, therapeutic treatment, determination of the presence of a tat419 protein, diagnosis of the presence of cancer and distribution of cytotoxic agent
WO2011123813A2 (en) 2010-04-02 2011-10-06 Amunix Operating Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
SG185027A1 (en) 2010-05-03 2012-11-29 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
US20130150286A1 (en) 2010-06-25 2013-06-13 Jean-Claude Sirard Methods and pharmaceutical compositions for the treatment of respiratory tract infections
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
ES2972902T3 (en) 2010-08-17 2024-06-17 Ambrx Inc Modified relaxin polypeptides and their uses
CN102380091A (en) 2010-08-31 2012-03-21 健能隆医药技术(上海)有限公司 Application of interleukin-22 in curing virus hepatitis
CN103797026A (en) 2010-09-15 2014-05-14 阿利吉那科技有限公司 Bioproduction of aromatic chemicals from lignin-derived compounds
TWI480288B (en) 2010-09-23 2015-04-11 Lilly Co Eli Formulations for bovine granulocyte colony stimulating factor and variants thereof
US20140199682A1 (en) 2010-11-17 2014-07-17 Sea Lane Biotechnologies, Llc Influenza neutralizing agents
WO2013163606A1 (en) 2012-04-27 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Vascular endothelial growth factor antagonists and methods for their use
PT3611180T (en) 2013-03-15 2022-03-15 Biomolecular Holdings Llc Hybrid immunoglobulin containing non-peptidyl linkage
CN104623637A (en) 2013-11-07 2015-05-20 健能隆医药技术(上海)有限公司 Application of IL-22 dimer in preparation of intravenous injection drugs
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
EP3116486B1 (en) 2014-03-14 2019-12-04 Daniel J. Capon Hybrid immunoglobulin containing non-peptidyl linkage
MX2017004947A (en) 2014-10-24 2017-06-29 Bristol Myers Squibb Co Modified fgf-21 polypeptides and uses thereof.
ES2930351T3 (en) 2016-04-15 2022-12-09 Evive Biotechnology Shanghai Ltd An IL-22 dimer for use in the treatment of necrotizing enterocolitis
EP3526248A4 (en) 2016-10-17 2020-07-08 Musc Foundation for Research Development COMPOSITIONS AND METHODS FOR TREATING LESIONS OF THE CENTRAL VENEER SYSTEM
ES2963839T3 (en) 2017-02-08 2024-04-02 Bristol Myers Squibb Co Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
EP4230649A3 (en) 2017-04-25 2023-10-25 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
US11827669B2 (en) 2017-07-19 2023-11-28 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection
WO2019089544A1 (en) 2017-11-01 2019-05-09 Tufts Medical Center, Inc. Bispecific antibody constructs and methods of use
EP3788071A1 (en) 2018-05-02 2021-03-10 The United States Of America, As Represented By The Secretary, Department of Health and Human Services Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
CN108676786B (en) * 2018-05-31 2021-02-23 大连民族大学 Culture medium for producing lipase by fermenting torticola terricola and culture method thereof
EP4136211A1 (en) 2020-04-15 2023-02-22 Genentech, Inc. Copper loss mitigation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE448386B (en) * 1978-10-18 1987-02-16 Sandoz Ag NEW CYCLOSPORIN DERIVATIVES, PROCEDURE FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITION CONTAINING THEM
FR2569723B1 (en) * 1984-08-31 1986-09-19 Centre Nat Rech Scient APPLICATION OF ANTIBIOTICS FROM THE PHLEOMYCIN FAMILY AS A SELECTION AGENT IN THE FIELD OF GENETIC ENGINEERING
EP0625577A1 (en) * 1985-08-29 1994-11-23 Genencor International, Inc. Heterologous polypeptides expressed in filamentous fungi, processes for their preparation, and vectors for their preparation
GB8610600D0 (en) * 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma

Also Published As

Publication number Publication date
WO1991000357A1 (en) 1991-01-10
EP0433431A1 (en) 1991-06-26
FR2649120A1 (en) 1991-01-04

Similar Documents

Publication Publication Date Title
FR2649120B1 (en) NOVEL STRAIN AND ITS MUTANTS OF FILAMENTOUS MUSHROOMS, PROCESS FOR PRODUCING RECOMBINANT PROTEINS USING SAID STRAIN, AND STRAINS AND PROTEINS OBTAINED BY SAID METHOD
FI103129B1 (en) Saccaharomyces cerevisiae strain and method for producing a protein heterologous to S. cerevisiae
FR2646437B1 (en) NOVEL DNA SEQUENCES, THEIR APPLICATION AS A SEQUENCE ENCODING A SIGNAL PEPTIDE FOR THE SECRETION OF MATURE PROTEINS BY RECOMBINANT YEASTS, EXPRESSION CASSETTES, PROCESSED YEASTS AND PROCESS FOR PREPARING THE SAME
KR900013082A (en) PF1022 substance, its production method and anthelmintic composition containing the substance
BE905227A (en) PROCESS FOR PRODUCING ETHANOL AND VARIOUS BY-PRODUCTS FROM CEREALS.
FR2559501B1 (en) PROCESS FOR ACTIVATION OF PROTEIN PRODUCTION BY CELL CULTURES
FR2607071B1 (en) PROCESS FOR FORMING ARTICLES REINFORCED BY FILAMENTS AND ARTICLES THEREOF
JPS6437295A (en) Production of l-threonine by fermentation
FR2609018B1 (en) PROCESS FOR PRODUCING LIGHT-TRANSMITTING CALCIUM PHOSPHATE GLASS CERAMIC
DK459989D0 (en) YEAR PROCESS
FR2562067B1 (en) PROCESS FOR THE SEPARATION OF A BASIC AMINO ACID FROM ITS FERMENTATION BROTH
BR9508280A (en) High-intensity steel item manufacturing process
ES2119006T3 (en) MUTANT STRAIN OF STREPTOCOCCUS ZOOEPIDEMICUS TO PREPARE HYALURONIC ACID.
FR2476085B1 (en) COMPOUNDS OBTAINED BY CULTURE OF MICROORGANISMS BELONGING TO THE BACILLUS STRAIN AND METHOD FOR OBTAINING THEM
FR2635334B1 (en) PROCESS FOR PRODUCING LACTIC ACID BY FERMENTATION
FR2637913B1 (en) PROCESS FOR PRODUCING POLYSACCHARIDES BY FERMENTATION OF A HYDROCARBON SOURCE USING MICROORGANISMS
BE899661A (en) PROCESS FOR INCREASING THE PRODUCTION OF ANTIBIOTICS BY GENETIC RECOMBINATION IN VIVO.
EA199700310A1 (en) BIOLOGICAL METHOD OF OBTAINING COMPOUNDS OF DIPEPTID NATURE
BE884889A (en) PROCESS FOR PRODUCING INTERMEDIATE COMPOUNDS FOR OBTAINING SPECTINOMYCIN AND THE LIKE THEREOF AND PRODUCTS THEREOF
SE9002668L (en) PROCEDURES FOR PREPARING ACTIVE MASS OF PREPARING QUALITY FROM WASTE OF ACTIVE MASS AS PREPARED IN PREPARATION OF BLYUM CUMULATORS
BR9404659A (en) Amorphous boric oxide product and process for its production
FR2627928B1 (en) PROCESS FOR PRODUCING A SPEAKER MEMBRANE IN TOTALLY CARBONATED MATERIALS
FR2630888B1 (en) PROCESS FOR INCREASING THE PRODUCTIVITY OF SOWS
FR2573429B1 (en) NOVEL THIENOPYRIDINE DERIVATIVES AND A PROCESS FOR THEIR PREPARATION
BE883552A (en) IMPROVEMENT IN THE METHOD FOR ADJUSTING THE WIDTH OF A GLASS RIBBON PRODUCED BY A FLEET GLASS PRODUCTION PROCESS